Shire said results of study show lanadelumab cut down on the rate of monthly hereditary angioedema episodes by 87 percent.
Shire said in a release the data comes from its study in which hereditary angioedema sufferers 12 and older received either 300 milligrams injections of lanadelumab every two or a placebo over half a year.
Shire said hereditary angioedema sufferers receiving lanadelumab saw their average rate of hereditary angioedema episodes go down 87 percent in contrast to those who had the placebo.
Of the hereditary angioedema sufferers who took part in the study, 52 percent had three or more attacks a month at the start of the study, 65 percent said they had had laryngeal attacks and 56 percent said they were on a long-term plan to fight the hereditary angioedema, the release said.
